Two from UK join Caligor Rx in US
Will lead quality assurance and clinical trial supplies
McKenna has a first class degree in Health and Social Care from the Open University in the UK. She was most recently responsible for building a quality assurance department at a supplier of comparator drugs.
May is a registered nurse and joins Caligor Rx after five years in comparator procurement for worldwide clinical trials. She was previously a senior manager in the NHS in the UK.
You may also like
Regulatory
FDA rejects Summit Therapeutics’ ivonescimab lung cancer drug
The US regulator has issued a complete response letter for the PD-1/VEGF bispecific antibody, citing a lack of statistically significant overall survival benefit in a Phase III trial despite improvements in progression-free survival
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part II)
How the enterprise trap is set: familiar platforms, borrowed requirements and hidden validation costs can turn seemingly safe purchasing decisions into costly operational burdens
Regulatory
EU combination products: MDR, article 117 and drug-device approval risks
Bringing a drug-device combination product to market in Europe requires more than a strong pharmaceutical dossier and a functional delivery device. Companies must align two different development models, satisfy EU MDR expectations, manage notified-body involvement, and demonstrate that the drug and device work safely as one integrated product
Regulatory
Is your combination product really submission-ready?
A pharmaceutical team may consider a combination product nearly ready because the clinical, stability, quality, and drug data are in place. At the same time, the device team may still be completing design verification, usability studies, risk-management activities, or notified-body preparation